Market revenue in 2023 | USD 53.5 million |
Market revenue in 2030 | USD 94.0 million |
Growth rate | 8.4% (CAGR from 2023 to 2030) |
Largest segment | Outsourcing |
Fastest growing segment | Outsourcing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | In-house, Outsourcing |
Key market players worldwide | Genpact Ltd, Criterium Inc., Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Labcorp Holdings Inc, FREYR Battery Inc, Pharmexon, Cambridge Design Partnership, Voisin Consulting Life Sciences, Accell, PAREXEL, Promedica International, PharmaLex, NDA Regulatory Service GmbH, QVigilance, BlueReg Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regulatory affairs market will help companies and investors design strategic landscapes.
Outsourcing was the largest segment with a revenue share of 58.13% in 2023. Horizon Databook has segmented the UAE regulatory affairs market based on in-house, outsourcing covering the revenue growth of each sub-segment from 2018 to 2030.
Currently, UAE is the third largest market for Regulatory Affairs in the MEA region since most market players are dependent on imports. Medical device regulations in the country are based on Australian TGA, EU, and U.S. regulations.
Products with approval from the Canadian, Australian, EU, and U.S. regulatory agencies are eligible for a short registration process in the UAE. The UAE Government is focused on attracting innovative drug manufacturers by 2021, with double the number of local companies producing patented drugs.
The country has a short drug registration system for both innovator and generic drugs approved by the U.S. FDA. Some of the examples of fast-tracked drugs in UAE are AbbVie’s Viekirax, Exviera (dasabuvir), and Eli Lilly's Trulicity.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE regulatory affairs market , including forecasts for subscribers. This country databook contains high-level insights into UAE regulatory affairs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account